Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03100942 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT03100942 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 152 participants.
The verdict
NCT03100942, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).
Interventions
- DRUG Tirabrutinib
- DRUG Filgotinib
- DRUG Lanraplenib
- DRUG Lanraplenib placebo
- DRUG Filgotinib placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2019-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03100942
The ClinicalTrials.gov registry entry for NCT03100942 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tirabrutinib is the first listed.
NCT03100942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03100942 about?
NCT03100942 is a clinical study titled "Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome". The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).
What is the current status of trial NCT03100942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2017-05-01. Estimated completion is 2019-10-02.
What interventions are being tested in trial NCT03100942?
The interventions under investigation include: Tirabrutinib (DRUG), Filgotinib (DRUG), Lanraplenib (DRUG), Lanraplenib placebo (DRUG), Filgotinib placebo (DRUG).
Who is sponsoring clinical trial NCT03100942?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.